Tirzide

Tirzide

 (2,114 Reviews)
$0.00
$0.00
SAVE Sold out

BUNDLE & SAVE

Tirzide

Tirzide

$0.00
$0.00
SAVE Sold out
View full details

Treats 4 Types of Disease withTirzepatide(Tirzide)

  • Overweight & Obesity

    Reduce weight upto 22%

  • Type 2 Diabetes Mellitus

    Superior HbA1c reduction up to less than 7%

  • Sleep Apnea

    Improve Obstructive Sleep Apnea (OSA) in obese patients

  • Cardiovascular Events

    Decreases the risk of cardiovascular events

    Tirzepatide(Tirzide) works with yourmetabolic hormone

    See how Tirzepatide can help peoplewith overweight and obesity

    • 48 lbs weight reduction

      Tirzepatide decreases upto 48 lbs in non-diabetes patient in 72 weeks trial

    • 48 lbs weight reduction

      Tirzepatide decreases upto 48 lbs in non-diabetes patient in 72 weeks trial

    • Reduce upto HbA1C <7%

      Tirzepatide reduces less than 7% of HbA1C in the 40 week clinical trial in patient taking with or without other diabetes medication

    • Neutralize the risk of cardiovascular event

      Tirzepatide decreases upto 48 lbs in non-diabetes patient in 72 weeks trial

      Built for International Healthcare Markets

      • Medical Governance

        Content aligned for healthcare professionals with indication boundaries and safety-forward communication.

      • Quality-First Positioning

        Brand narrative centered on manufacturing quality, traceability, and responsible therapeutic use.

      • Cross-Region Accessibility

        Multilingual interface support and structured pathways for verification, education, and contact.

        A Chronic Disease, Not Just a Number

        The brochure frames obesity as a chronic disease defined by excess fat accumulation and progressive cardiometabolic risk. Tirzepatide is positioned as a metabolic therapy that supports appetite regulation, weight reduction, glycemic control, and broader risk-factor improvement when paired with diet and activity.

        • Underweight

          BMI below 18.5

        • Normal

          BMI 18.5 to 24.9

        • Overweight

          BMI 25 to 29.9

        • Obesity

          BMI 30 and above

          Key Facts for Prescribers

          Approved Clinical Uses

          • Adjunct to diet and exercise for Type 2 Diabetes in adults
          • Chronic weight management (BMI ≥ 30, or ≥ 27 with comorbidity)
          • Mono or combination therapy per local label
          • Appropriate as add-on to basal insulin with monitoring

          Key Use Boundaries

          • Not for Type 1 diabetes or diabetic ketoacidosis
          • Not for cosmetic or short-term unsupervised use
          • Avoid concurrent use with other GLP-1 receptor agonists
          • Prescribe under qualified clinical supervision only

          Clinical Program Signals (Illustrative)

          • Colu~2% HbA1c

            Mean glycemic reduction range reported in key trial populations

          • 15%+ Weight

            Clinically meaningful body-weight reduction in eligible cohorts

          • Weekly Dose

            Simple once-weekly administration protocol to support adherence

          • 4 Strengths

            2.5 mg, 5 mg, 7.5 mg, and 10 mg available in local portfolio